Targeting Cell Survival Genes Using Antisense Oligonucleotides to Improve Chemo- and Hormonal-Therapies in Prostate Cancer

Author： Zellweger T. Miyake H. Chi K. July L. Kiyama S. Gleave M.

Publisher： Elsevier

ISSN： 1569-9056

Source： European Urology Supplements, Vol.1, Iss.2, 2002-05, pp. : 7-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemosensitisation of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor

By Hellawell G. Ferguson D. Brewster S. Macaulay V.

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 36-36

Elsevier

Access to resources Recommend Favorite

Hormonal therapy for prostate cancer: primum non nocere

By Milbank A.J. Dreicer R. Klein E.A.

Urology, Vol. 60, Iss. 5, 2002-11 ,pp. : 738-741

Elsevier

Access to resources Recommend Favorite

A 10-Year Clinical Experience with Intermittent Hormonal Therapy for Prostate Cancer

By Prapotnich D. Fizazi K. Escudier B. Mombet A. Cathala N. Vallancien G.

European Urology, Vol. 43, Iss. 3, 2003-03 ,pp. : 233-240

Elsevier

Access to resources Recommend Favorite

Combined hormonal and radiation therapy for lymph node-positive prostate cancer

By Whittington R. Malkowicz S.B. Barnes M.M. Broderick G.A. Van Arsdalen K. Dougherty M.J. Wein A.J.

Urology, Vol. 46, Iss. 2, 1995-08 ,pp. : 213-219

Elsevier

Access to resources Recommend Favorite

Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer

By Balaji K.C. Koul H. Mitra S. Maramag C. Reddy P. Menon M. Malhotra R.K. Laxmanan S.

Urology, Vol. 50, Iss. 6, 1997-12 ,pp. : 1007-1015

Elsevier

Access to resources Recommend Favorite